Success Story: NIW Approval for a Biomedical Science Researcher Advancing Cancer Drug Resistance Studies
Client’s Testimonial:
"I would also like to extend my sincere gratitude for your hard work, guidance, and support throughout this process. I truly appreciate the effort that you and your team invested in preparing and securing the approval of my petition."
On May 7th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Research Fellow in the Field of Biomedical Science (Approval Notice).
General Field: Biomedical Science
Position at the Time of Case Filing: Research Fellow
Country of Origin: Nepal
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: May 7th, 2026
Processing Time: 21 months, 12 days (Premium Processing Upgrade Requested)
Case Summary:
We are pleased to share the approval of an I-140 National Interest Waiver petition for a client with a PhD in pharmacy and expertise in biomedical science. The client’s proposed endeavor focuses on utilizing state-of-the-art genetic, molecular biology, and epigenetic techniques to determine drug resistance mechanisms in cancer cells. Through this work, the client aims to develop strategies for novel treatment targets that may help overcome cancer drug resistance and improve treatment outcomes.
The petition demonstrated the national importance of the client’s work by connecting the proposed endeavor to the need for more effective cancer therapies. Rather than presenting the client’s research as a narrow laboratory interest, the petition explained how identifying mechanisms of resistance can support the development of treatment strategies that improve patient care, reduce the burden of ineffective therapies, and strengthen biomedical innovation in the United States.
To show that the client was well-positioned to advance this endeavor, the petition highlighted the following credentials:
- 11 peer-reviewed journal articles, including 6 first-authored publications
- 2 conference abstracts and 1 pre-print
- 108 citations to the client’s published research
- At least 3 completed peer reviews
- Research funding support from the National Institutes of Health, the National Research Foundation of Korea, and IPET
These credentials were not treated as automatically sufficient. The petition explained that the publication record showed sustained productivity, while the citation count demonstrated that independent researchers had relied on the client’s findings in their own studies. The peer-review activity further supported the argument that journals recognized the client’s expertise and trusted the client to evaluate the work of others in related areas of biomedical science.
The approval of this I-140 NIW petition recognized the strength of a case built around a clearly defined biomedical endeavor, advanced academic training, peer-reviewed research, independent citation evidence, peer-review activity, and funding support. By presenting the client’s work as part of the broader effort to understand and overcome cancer drug resistance, the petition successfully demonstrated both the national importance of the proposed endeavor and the client’s ability to continue advancing it.
We congratulate the client on this NIW approval and look forward to the client’s continued contributions to biomedical science, cancer research, and the development of improved therapeutic strategies.